Since its inception in 2005, The Cure Parkinson’s Trust (CPT) has challenged the view that there is no cure for Parkinson’s (PD). We only accept to fund projects that can demonstrate the potential to slow, stop, or even reverse the condition. We actively encourage collaboration between scientists and foster these relationships to accelerate progress.

Our research committee not only interrogates new proposals but also analyses the reports received from the research we are funding to ensure that the science is robust, progress is effective and results will be disseminated rapidly so PD researchers can learn from their findings and ultimately benefit those people living with Parkinson's.

Our Impact:

We have funded the development of a new way of delivering drugs with pin-point precision into the brain. This device is now being used in a ground-breaking trial in Bristol delivering a growth factor into patients brains. Results from this trial are expected Spring 2017.

We approved funding for the University of Edinburgh stem cell research and the TRANSEURO Trial in Cambridge, regenerative trials using stem cells to potentially reverse Parkinson's. Both trials have pioneered the groundwork for future trials using stem cells in terms of patient selection and the transplant process.

We funded and created the first clinical trial using a type II diabetes treatment (Exenatide) as a potential new therapy for PD. The initial study prompted further critical questions around the possible link between insulin resistance and the development of PD. In parallel, two further trials using two different diabetes treatments (GLP-1 agonists) were funded so opening up this potentially important category of drugs in treating PD.

We have funded work to understand whether paradoxical kinesis could be used as a viable treatment route – this is the phenomena experienced by many people with Parkinson’s whereby there is a fleeting override of symptoms in situations of urgency and the body's innate automatic response.

We have investigated calcium channel blockers and mitochondrial dysfunction in Parkinson’s to see if these provide opportunities for targeted development of new treatments. And we have funded drug discovery work and drug screens to identify specific drug targets in Parkinson’s, be that of genetic predisposition, alpha-synuclein aggregation, oxidation and inflammation, or growth factors.

Our pioneering drug repurposing programme - Linked Clinical Trials - looks at drugs that are already used to treat other diseases which could potentially be used in Parkinson's to slow, stop or reverse the condition.

If you are inspired by the work of The Cure Parkinson's Trust please consider donating today.